IMMP

Immutep

Fundamental data last updated:March 2, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

Nasdaq

County of HQ

Australia

Next Earnings Date

-

Business Summary

Immutep is a biotechnology company that develops novel immunotherapies for the treatment of cancer and autoimmune diseases. Its lead product candidate is based on the LAG-3 immune control mechanism, which plays a vital role in regulating T cell response.

 


Analyze IMMP on TradingView

VALUATION

P/E

-

Market Cap ($M USD)

$402

Forward P/E

-

PEG

-

PRICE TO SALES

-

PRICE TO BOOK

3.6

EV / EBITDA

5-Year Average P/E

Free Cash Flow Yield

DCF Value

Graham Number

Price to FCF

EV to FCF

Earnings Yield

FCF Yield

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$0.28

Next Year EPS Growth Estimate

-$0.24

Next Year Revenue Growth Estimate

-62.50%

Return on Equity (ROE)

-42.80%

FREE CASH FLOW

Operating Margin

-

Debt-to-Equity

0

Piotroski F-Score

Altman Z-Score

Return on Invested Capital (ROIC)

Current Ratio

Quick Ratio

Net Debt to EBITDA

Interest Coverage

Gross Profit margin

FCF PER SHARE

REVENUE PER SHARE

Analyze IMMP on TradingView

Gainseekers Quantitative Analysis

Summary

Immutep is a biotechnology company with a market capitalization of $402 million. The company is currently unprofitable, with an EPS of -$0.28 and a Return on Equity of -42.80%. It trades at a Price / Book multiple of 3.6 and maintains a Debt / Equity ratio of 0.

AI Exposure / Tech Reliance

The provided data does not contain information regarding the company's AI exposure or technology reliance.

The Bull Case

Analysts have a Consensus Rating of 1 for the stock, with a Mean Consensus Target Price of $9.67. The company has a Debt / Equity ratio of 0, and its estimated EPS for next year of -$0.24 indicates a projected narrowing of losses.

The Bear Case

The company is unprofitable with a Return on Equity of -42.80% and is projected to experience a Sales Growth decline of -62.50% next year. Institutional Ownership is low at 2.10%, and the Short % of Float is 3.20%.

Market Sentiment & Smart Money

Short Interest %

3.20%

Analyst Consensus

1

Average Analyst Price Target

$9.67

Institutional Ownership %

2.10%

1-Year Beta

Insider Buying % (6 Mo)

Distance to 52-Week High

Distance to 52-Week Low

EARNINGS SURPRISE %

50-DAY SMA

200-DAY SMA

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.